The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
Eloxx Pharmaceuticals Q2 EPS $(0.54) Down From $(0.20) YoY
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported quarterly losses of $(0.54) per share. This is a 170 percent decrease over losses of $(0.20) per share from the same period last year.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
Monday morning, 285 companies reached new 52-week lows.
Eloxx Pharma Sees Data Readout From First Four Arms Of Cystic Fibrosis Study By End Of 2021
Eloxx Pharmaceuticals Inc (NASDAQ:ELOX) provided an enrollment update for the ongoing Phase 2 trial of ELX-02 to treat cystic fibrosis (CF)…
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X